Skip to content
ppharmaranks
Menu
Class IIOngoing

Duloxetine D/R recall

FDA recall D-0567-2025 · initiated Mar 7, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Aug 13, 2025How we research

Direct Rx recalled Duloxetine D/R in Mar 2025 — an FDA Class II recall (D-0567-2025) because CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: 02AU2406, Exp 01/31/2027

Quantity recalled: 16 bottles

Details

Product
Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, NDC 61919-422-30
Recalling company
Direct Rx
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide
Initiated
Mar 7, 2025
FDA report date
Aug 13, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Duloxetine D/R recalled?
Direct Rx recalled Duloxetine D/R in Mar 2025 — an FDA Class II recall (D-0567-2025) because CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Duloxetine D/R recalled?
Per the FDA enforcement record, the reason for recall D-0567-2025 was: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Is a recalled Duloxetine D/R dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Duloxetine D/R are affected?
Distributed: Nationwide. The recall covers these lots — Lot #: 02AU2406, Exp 01/31/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0567-2025.

Source: openFDA Drug Enforcement record D-0567-2025

← All drug recalls